100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AR077353
Award Date
8/15/20
Completion Date
7/30/22
Dollars Obligated
$250K
Overview
Activity
2
Transactions
2
Subawards
Similar Awards
Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Awardee
Biostrategies LC (PE6MEQZRFW63)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Update #1
Update #2
TREATMENT OF MUSCULAR SYMPTOMS IN POMPE RARE DISEASE VIA LECTIN ASSISTED ERT DELIVERY
Posted 8/11/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
TREATMENT OF MUSCULAR SYMPTOMS IN POMPE RARE DISEASE VIA LECTIN ASSISTED ERT DELIVERY - THE CURRENT INABILITY TO EFFECTIVELY DELIVER CORRECTIVE DOSES OF LYSOSOMAL ENZYMES TO KEY CELLS INVOLVED IN MUSCULAR DISEASE SYMPTOMS REMAINS A SIGNIFICANT HURDLE FOR RARE LYSOSOMAL DISORDERS (LSD) SUCH AS POMPE DISEASE AND OTHER SIMILAR DISEASES WITH SIGNIFICANT MUSCULAR-SKELETAL PATHOLOGIES. BIOSTRATEGIES LC IS DEVELOPING THE PLANT LECTIN RTB AS A CARRIER CAPABLE OF EXPANDING ENZYME DELIVERY TO "HARD-TO-TREAT" ORGANS AND TISSUES INCLUDING THE BRAIN, HEART, AND SKELETAL MUSCLE TISSUES. LECTIN-MEDIATED ERT DELIVERY HAS RECENTLY SHOWN PROMISE IN OTHER LSDS INCLUDING MPS I AND GM1. THIS SBIR IS FOCUSED ON DEVELOPING A "DELIVERY-ENHANCED" ENZYME REPLACEMENT THERAPY (ERT) FOR PATIENTS WITH POMPE DISEASE. POMPE IS AN AUTOSOMAL RECESSIVE LSD CAUSED BY GENETIC DEFICIENCIES IN ACID ALPHA-GLUCOSIDASE (GAA) LEADING TO PROGRESSIVE MULTI-ORGAN PATHOLOGIES PARTICULARLY FOCUSED ON SEVERE SYMPTOMS IN SMOOTH, CARDIAC AND SKELETAL MUSCLES. POMPE DISEASE IN ITS SEVERE FORMS CAN LEAD TO DEATH DUE TO EXTENSIVE CARDIOMYOPATHY AND RESPIRATORY MUSCLE FAILURE. OUR LONG-TERM GOAL IN THIS RESEARCH PROJECT IS TO BRING AN ERT CAPABLE OF TREATING THE FULL SPECTRUM OF PROGRESSIVE MUSCULAR AND OTHER DISEASE MANIFESTATIONS TO POMPE PATIENTS. OBJECTIVES OF THIS PHASE I SBIR FEASIBILITY STUDY ARE TO PRODUCE BIOACTIVE GAA:RTB FUSIONS AND DEMONSTRATE ERT PRODUCT DELIVERY INTO HUMAN MYOCYTES, CORRECTION OF LYSOSOMAL PHENOTYPE IN POMPE CELLS, AND BIODISTRIBUTION TO SKELETAL MUSCLE, HEART, AND OTHER TISSUES IN THE POMPE MOUSE MODEL. SUCCESS IN PHASE I FEASIBILITY GOALS WILL SUPPORT MOVING ON TO RIGOROUS PHASE II SBIR FOLLOW- UP PRECLINICAL ASSESSMENTS AIMED AT MOVING THIS PROMISING ERT PRODUCT TO AN IND. THE FEASIBILITY ESTABLISHED HERE WILL ALSO SUPPORT EXPANDING THE RTB CARRIER SYSTEM TO ADDITIONAL ERT DRUGS AND THERAPEUTICS FOR OTHER DISEASES HAVING LIFE-THREATENING MUSCLE PATHOLOGIES.
$0
5/2/23
Not listed
TREATMENT OF MUSCULAR SYMPTOMS IN POMPE RARE DISEASE VIA LECTIN ASSISTED ERT DELIVERY
$250.0k
8/11/20